Blue Shield of California

Health plan provider

Based in CA

Share:𝕏LinkedInFacebook
🤖

AI Overview

With $1.5M in lobbying spend across 30 quarterly filings, Blue Shield of California is a significant lobbying presence. They deploy 31 individual lobbyists Their lobbying covers 4 issue areas. Active from 2018 to 2025.

$1.5M
Total Spend
8
Years Active
1
Firms Hired
31
Lobbyists Deployed
4
Issues Lobbied

Spending Trend

View as table
YearLobbying Spend
2018$200K
2019$200K
2020$200K
2021$200K
2022$150K
2023$200K
2024$150K
2025$200K

Issues Lobbied

PharmacyHealth IssuesInsuranceMedicare/Medicaid

Lobbying Firms

Mehlman Consulting, INC.

Lobbyists

Charles WootersSohini GuptaDean RosenDavid ThomasElise Finley PickeringDavid CastagnettiBruce MehlmanSage EastmanLauren AronsonMichael RobinsonMichael CollinsConstantine HingsonHelen TolarSteve HaroNichole DistefanoMckenzie BricePaul ThornellStephen CoteAlexander PerkinsVictoria FloodRosemary GutierrezZachary MalloveCaitlin Van SantLisa GoldmanAlyene MlinarErica ChabotAnnie WolfNaveen ParmarJon AdameJoseph BrownEarl Flood

What They Lobby About

These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Pharmacy, Health Issues, Insurance, Medicare/Medicaid

Issues related to health insurance and prescription drug pricing.

Issues related to health insurance and prescription drug pricing.

S. 974 - The CREATES Act of 2017.

Issues related to health insurance and prescription drug pricing.

Re-insurance and ACA cost sharing reduction policies.

H.R. 4666 - Premium Relief Act of 2017.

S. 974 - The CREATES Act of 2017.

Issues related to health insurance and prescription drug pricing.

H.R. 4666 - Premium Relief Act of 2017.

S. 974 - The CREATES Act of 2017.

H.R. 6 - SUPPORT for Patients and Communities Act.

S. 3120 - HEAL Act of 2018

ESRD Proposed Payment Policy Rule

Issues related to health insurance and prescription drug pricing.

S. 974 - The CREATES Act of 2017.

H.R. 6 - SUPPORT for Patients and Communities Act.

S. 3120 - HEAL Act of 2018

ESRD Proposed Payment Policy Rule

Issues related to health insurance and prescription drug pricing.

S. 974 - The CREATES Act of 2017.

H.R. 6 - SUPPORT for Patients and Communities Act.

S. 3120 - HEAL Act of 2018

Issues related to health insurance and prescription drug pricing.

H.R. 4666 - Premium Relief Act of 2017.

S. 974 - The CREATES Act of 2017.

H.R. 6 - SUPPORT for Patients and Communities Act.

S. 3120 - HEAL Act of 2018

Prescription drug pricing.

Showing 8 of 20 unique descriptions from filings.

Related Analysis

📈 Client Trajectories
See how this client compares to others over time
🎯 Market Concentration
How concentrated is the lobbying market?
🚀 Spending Momentum
Which issues are surging right now?
🏭 Pharma Lobbying
Industry overview and top spenders

Related Investigations

Big Pharma's $452M Lobbying Machine
How pharmaceutical companies spend hundreds of millions to influence health policy.
Healthcare's $3 Billion Bet
The healthcare industry's massive lobbying investment.
Federal Lobbying Statistics 2025
The definitive stats — $15.2B total, industry breakdowns, and trends.
What Is Lobbying? A Complete Guide
How lobbying works, who does it, and why it matters.

Explore More

← All Clients⚖️ Compare Clients💵 ROI Calculator🔍 Investigations📖 How Lobbying Works🕸️ Network Analysis

Data Sources: Senate LDA Filings

Last updated: February 2026

This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.